Literature DB >> 7517424

ME1 epitope of HLA-B27 confers class I-mediated modulation of gram-negative bacterial invasion.

K Kapasi1, R D Inman.   

Abstract

We have previously demonstrated that the presence of the MHC class I molecule, HLA-B27, on the surface of transfected fibroblasts differentially alters Gram-negative bacterial invasion as compared with class I alleles that are not implicated in the seronegative spondyloarthropathies. We have now extended this analysis to show that fibroblasts transfected with HLA-B7, a cross-reactive allele with HLA-B27, also demonstrate a similar altered bacterial invasion phenotype. The decrease in the ability of the bacteria to penetrate the HLA-B27 and HLA-B7 transfectants is an invasion-mediated event, as demonstrated by differential invasion events using Escherichia coli transfected with the inv gene of Yersinia enterocolitica. The lysine at position 70, although unique to the HLA-B27 subtypes, is shown to be not involved in mediating the decrease in invasion. However, the ME1 epitope is the critical factor in determining allele-specific alteration in invasion on the basis of the following: 1) ME1 mAb preincubation reverses the decrease; 2) ME1-binding alleles act like HLA-B27; 3) a class I allele that is intermediate in ME1 binding (HLA-B14) also demonstrates a relative decrease in invasion; and 4) mutation at residue 67 (C-->Y) in HLA-B27, which eliminates the ME1 epitope, normalizes the decreased invasion seen in the native HLA-B27-transfected cells. Thus, the ME1 epitope relates to the disease susceptibility for reactive arthritis that is conferred by both HLA-B27 and cross-reactive group Ags.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517424

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  [Rheumatology update. Current knowledge of etiology, pathophysiology, diagnosis, and therapy of selected arthritic disorders. Part I: pathogenesis and differential diagnosis].

Authors:  G Hein; P Oelzner; H Sprott; B Manger
Journal:  Med Klin (Munich)       Date:  1999-09-15

Review 2.  Reactive arthritis or chronic infectious arthritis?

Authors:  J Sibilia; F-X Limbach
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

Review 3.  HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.

Authors:  Inés Colmegna; Raquel Cuchacovich; Luis R Espinoza
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

4.  HLA-B27 modulates the survival of Salmonella enteritidis in transfected L cells, possibly by impaired nitric oxide production.

Authors:  M Virtala; J Kirveskari; K Granfors
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

5.  The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms.

Authors:  Jane Zochling; Martin H J Bohl-Bühler; Xenofon Baraliakos; Ernst Feldtkeller; Jürgen Braun
Journal:  Clin Rheumatol       Date:  2005-12-23       Impact factor: 2.980

6.  Human HLA-B27 gene enhances susceptibility of rats to oral infection by Listeria monocytogenes.

Authors:  T F Warner; J Madsen; J Starling; R D Wagner; J D Taurog; E Balish
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

7.  Invasion and persistence of Salmonella in human fibroblasts positive or negative for endogenous HLA B27.

Authors:  H I Huppertz; J Heesemann
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

8.  Human gamma delta T-cell recognition of Yersinia enterocolitica.

Authors:  J L Young; J C Goodall; H Beacock-Sharp; J S Gaston
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

9.  HLA-B27 expression does not modulate intracellular Chlamydia trachomatis infection of cell lines.

Authors:  J L Young; L Smith; M K Matyszak; J S Gaston
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 10.  Juvenile onset spondyloarthropathies: therapeutic aspects.

Authors:  R Burgos-Vargas
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.